Lv72
3580 积分 2024-04-21 加入
Engineered exoASO-STAT6: a potent monotherapy for oral squamous cell carcinoma
1天前
已完结
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
24天前
已完结
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial
29天前
已完结
Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic Dermatitis
29天前
已完结
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
29天前
已完结
Strategies and Recommendations for Using a Data‐Driven and Risk‐Based Approach in the Selection of First‐in‐Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment
1个月前
已完结
Hepatic glucose metabolism in the steatotic liver
1个月前
已完结
Geroscience
1个月前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
1个月前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
1个月前
已完结
皖公网安备34019202002308
